| Drug / Therapy | Generalized |
| Indication | VNDA PDUFA |
| Decision Type | PDUFA |
| Conditions | VNDA PDUFA |
| Interventions | Generalized |
Vanda Pharmaceuticals (VNDA) operates in the Neuroscience sector. The current BiotechSign Score is 50 (Grade: D).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The PDUFA date for Generalized by Vanda Pharmaceuticals (VNDA) is scheduled for December 12, 2026. This is the target date for the FDA to make a decision on this application.
Generalized is being developed by Vanda Pharmaceuticals for the treatment of VNDA PDUFA. It is under FDA review.
If Generalized receives FDA approval, Vanda Pharmaceuticals (VNDA) would be able to market the drug in the United States for VNDA PDUFA. This typically leads to significant stock price movement for biotech companies. Investors should monitor the PDUFA date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for VNDA on DilutionWatch at dilutionwatch.com/stock/VNDA.html.
You can view the full BiotechSign company profile for Vanda Pharmaceuticals (VNDA) at biotechsign.com/app/company/VNDA, which includes the BiotechSign Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSign is not a registered investment advisor.